Infectious Diseases Institute, Uganda
16
2
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.3%
1 terminated/withdrawn out of 16 trials
90.0%
+3.5% vs industry average
25%
4 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Integrating HIV Prevention With TB Household Contact Evaluation in Uganda
Role: collaborator
Use of Unmanned Air Vehicles (Medical Drones) to Overcome Geographical Barriers to Delivery of Anti-Retroviral Therapy and Biological Samples
Role: collaborator
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
Role: collaborator
Randomized Controlled Trial of Game Changers
Role: collaborator
Dolutegravir in Pregnant HIV Mothers and Their Neonates
Role: collaborator
Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women
Role: collaborator
Call for Life Youth ART Adherence Study
Role: collaborator
The Lived Experience of Participants in an African Randomised Trial
Role: collaborator
FujiLAM Prospective Evaluation Trial
Role: collaborator
Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa
Role: collaborator
Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma
Role: collaborator
Nucleosides And Darunavir/Dolutegravir In Africa
Role: collaborator
Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda
Role: collaborator
Cryptococcal Antigen Screening Plus Sertraline
Role: collaborator
Operational Research for Cryptococcal Antigen Screening
Role: collaborator
Syphilis Treatment of Partners Trial
Role: collaborator
All 16 trials loaded